| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | JUNO THERAPEUTICS INCORPORATED | 1,329,512 | 54,098,000 | 30.46% | ||
| 2 | PARATEK PHARMACEUTICALS INC | 2,138,872 | 40,639,000 | 22.88% | ||
| 3 | Egalet Corp | 2,645,558 | 34,868,000 | 19.63% | ||
| 4 | FIBROGEN INC COM | 872,175 | 19,118,000 | 10.76% | ||
| 5 | Nabriva Therapeutics AG | 1,145,890 | 10,886,000 | 6.13% | ||
| 6 | ESSA Pharma | 1,090,909 | 6,884,000 | 3.88% | ||
| 7 | Pieris Pharmaceuticals | 2,483,949 | 4,546,000 | 2.56% | ||
| 8 | Proteon Therapeutics | 250,000 | 3,478,000 | 1.96% | ||
| 9 | Dicerna Pharmaceuticals | 223,457 | 1,835,000 | 1.03% | ||
| 10 | CymaBay Therapeutics | 650,000 | 1,261,000 | 0.71% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-15-010742, filed 2015.11.04).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
